CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Iterum Therapeutics PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Iterum Therapeutics PLC
Fitzwilliam Court
1st Floor, Leeson Close, Dublin 2
Phone: +353 16694820p:+353 16694820 DUBLIN, D02 YW24  Ireland Ticker: ITRMITRM
Business Summary
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, CEO and Director Corey N.Fishman
Independent Chairman of the board Brenton K.Ahrens 59 6/13/2019 11/1/2015
Chief Scientific Officer Michael W.Dunne
18 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Iterum Therapeutics International Ltd BLOCK 2 FLOOR 3 HARCOURT CENTRE DUBLIN Ireland
Iterum Therapeutics Bermuda Ltd CLARENDON HOUSE HAMILTON Bermuda
Iterum Therapeutics US Holding Ltd 200 S. WACKER DRIVE CHICAGO Illinois United States
Iterum Therapeutics US Ltd 200 S. WACKER DRIVE CHICAGO Illinois United States

Business Names
Business Name
Iterum Therapeutics Bermuda Limited
Iterum Therapeutics International Limited
Iterum Therapeutics US Holding Limited
Iterum Therapeutics US Limited
ITRM

General Information
Number of Employees: 14 (As of 2/29/2024)
Outstanding Shares: 16,426,784 (As of 2/29/2024)
Shareholders: 5
Stock Exchange: NASD
Federal Tax Id: 981283148


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024